Your browser doesn't support javascript.
loading
Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial.
Jering, Karola S; Claggett, Brian L; Pfeffer, Marc A; Granger, Christopher B; Køber, Lars; Lewis, Eldrin F; Maggioni, Aldo P; Mann, Douglas L; McMurray, John J V; Prescott, Margaret F; Rouleau, Jean L; Solomon, Scott D; Steg, Phillippe Gabriel; von Lewinski, Dirk; Braunwald, Eugene.
Afiliação
  • Jering KS; Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School Boston, MA (K.S.J., B.L.C., M.A.P., S.D.S., E.B.).
  • Claggett BL; Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School Boston, MA (K.S.J., B.L.C., M.A.P., S.D.S., E.B.).
  • Pfeffer MA; Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School Boston, MA (K.S.J., B.L.C., M.A.P., S.D.S., E.B.).
  • Granger CB; Division of Cardiology, Duke University School of Medicine, Durham, NC (C.B.G.).
  • Køber L; Heart Centre, Ringshospitalet Copenhagen University Hospital, Denmark (L.K.).
  • Lewis EF; Division of Cardiovascular Medicine, Stanford University School of Medicine, Palo Alto, CA (E.F.L.).
  • Maggioni AP; ANMCO Research Center, Heart Care Foundation, Florence, Italy (A.P.M.).
  • Mann DL; Department of Medicine, Washington University, St Louis, MO (D.L.M.).
  • McMurray JJV; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Scotland (J.J.V.M.).
  • Prescott MF; Novartis Pharmaceutical Corporation, East Hanover, NJ (M.F.P.).
  • Rouleau JL; Institut de Cardiologie de Montréal, Université de Montréal, QB, Canada (J.L.R.).
  • Solomon SD; Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School Boston, MA (K.S.J., B.L.C., M.A.P., S.D.S., E.B.).
  • Steg PG; Université Paris-Cité, Institut Universitaire de France, AP-HP (Assistance Publique-Hôpitaux de Paris), FACT (French Alliance for Cardiovascular Trials) and INSERM U-1148, Paris, France (P.G.S.).
  • von Lewinski D; Department of Cardiology, Medical University of Graz, Austria (D.v.L.).
  • Braunwald E; Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School Boston, MA (K.S.J., B.L.C., M.A.P., S.D.S., E.B.).
Circ Heart Fail ; 16(5): e010259, 2023 05.
Article em En | MEDLINE | ID: mdl-37125529
ABSTRACT

BACKGROUND:

NT-proBNP (N-terminal pro-B-type natriuretic peptide) is a potent predictor of death and heart failure (HF) across multiple populations. We evaluated the prognostic importance of NT-proBNP in patients with acute myocardial infarction (MI) complicated by left ventricular systolic dysfunction, pulmonary congestion, or both and ≥1 of 8 risk-augmenting factors enrolled in the PARADISE-MI trial (Prospective ARNI vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After Myocardial Infarction).

METHODS:

Patients were randomized to sacubitril/valsartan 200 mg or ramipril 5 mg twice daily within 0.5 to 7 days of a MI. Patients with prior HF were excluded. NT-proBNP and hs-cTnT (high-sensitivity troponin T) were collected at randomization in a prespecified substudy of 1129 patients. The primary end point of PARADISE-MI was a composite of cardiovascular death or incident HF (hospitalization or outpatient symptomatic HF), analyzed as time-to-first event; additional end points included all-cause death and the composite of fatal or nonfatal MI or stroke.

RESULTS:

Median NT-proBNP was 1757 ng/L (25th-75th percentiles, 896-3462 ng/L) at randomization (4.0±1.8 days after the index MI). Patients in the highest quartile of NT-proBNP were older, more commonly women and had more hypertension, atrial fibrillation, renal dysfunction, and pulmonary congestion on presentation (all P<0.001). NT-proBNP was strongly associated with the primary end point (adjusted hazard ratio, 1.45 per doubling of NT-proBNP; [95% CI, 1.23-1.70]), adjusted for clinical variables and baseline hs-cTnT. NT-proBNP was also independently associated with all-cause death (adjusted hazard ratio, 1.74 [95% CI, 1.38-2.21]) and fatal or nonfatal MI or stroke (adjusted hazard ratio, 1.24 [95% CI, 1.05-1.45]). NT-proBNP did not significantly modify the neutral treatment effect of sacubitril/valsartan relative to ramipril (P interaction=0.46).

CONCLUSIONS:

Within the first week of a high-risk MI NT-proBNP is associated with incident HF, death and atherosclerotic events. This prognostic information is independent of hs-cTnT. REGISTRATION URL https//www. CLINICALTRIALS gov; Unique identifier NCT02924727.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Insuficiência Cardíaca / Infarto do Miocárdio Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Circ Heart Fail Assunto da revista: ANGIOLOGIA / CARDIOLOGIA Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Insuficiência Cardíaca / Infarto do Miocárdio Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Circ Heart Fail Assunto da revista: ANGIOLOGIA / CARDIOLOGIA Ano de publicação: 2023 Tipo de documento: Article